Navigation Links
Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
Date:3/17/2008

CALGARY, March 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work characterizing immune system responses to administration of intravenous REOLYSIN(R) in a Phase I clinical trial. The paper, entitled "Characterization of the Adaptive and Innate Immune Response to Intravenous Oncolytic Reovirus (Dearing Type 3) during a Phase I Clinical Trial" appears online in the March 6, 2008 issue of Gene Therapy.

"This important work further defines the relationship between viral therapy and human immune response, and supports the development of our ongoing Phase II clinical trial program," said Dr. Brad Thompson, President and CEO of Oncolytics.

The investigators conducted a detailed analysis of the immune effects of intravenous viral therapy by collecting and analyzing immune response to the presence of the virus. The results suggest that reovirus may stimulate the immune system to mount a dynamic immune response to the presence of virus, increasing the potential to significantly enhance the efficacy of oncolytic virotherapy. About a third of those patients also showed increases in NK (natural killer) cells following therapy. The data support the development of interventions aimed at blunting the patient's immune response, although preclinical data also suggest that maintaining a baseline level is necessary to restrict systemic spread/toxicity of the virus.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information abo
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
2. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
3. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
4. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
5. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
6. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
7. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
8. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
9. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
10. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... your ear could improve the health of your heart, ... of Leeds used a standard TENS machine like those ... to the tragus, the small raised flap at the ... ear canal. , The stimulation changed the influence of ... nervous signals that can drive failing hearts too hard. ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
(Date:8/19/2014)... Pa. , Aug. 19, 2014 A ... has been nominated for a Centers for Disease Control ... addressing a major public health concern. ... System, is one of a team of researchers nominated ... Charles C. Shepard Science Award for Data Methods and ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... Jan. 9, 2012 Reportlinker.com announces ... is available in its catalogue: , ... Transplantation, Cord Blood Banking and Drug ... There is great interest ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... of the Company,s 2011 performance and accomplishments, as well as ... Initial 2011 Performance Results ... for 2011 (unaudited). , Over 21,000 total prenatal and ...
... today that it has secured $47.5 million in Series ... financing along with existing investors OrbiMed Advisors, New Enterprise ... financing, Josh Bilenker, M.D., Partner at Aisling Capital, will ... round will support commercialization of the company,s Atlas™ System ...
Cached Biology Technology:Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 2Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 3Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 4Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 5Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 6Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 2Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 3Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 4Roka Bioscience Secures $47.5 Million in Series D Financing 2
(Date:8/20/2014)... from the University of Tbingen, Arizona State University, the ... Public Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... least 1000 years old. The pathogen is a relative ... occasionally causes disease in humans today. These researchers assume ... Peruvian coast. "The link to sea lions was unexpected" ...
(Date:8/20/2014)... that acral melanomas the rare type of skin cancer ... distinct from other more common types of skin cancer, according ... Pigment Cell & Melanoma Research . , Acral melanoma ... the feet, nail-beds and other hairless parts of the skin. ... by UV damage from the sun. , The team, from ...
(Date:8/20/2014)... and plastic bags could one day be made out ... scientists are now reporting. The novel process they developed ... with its agricultural and plastic waste problems, appear in ... Ilker S. Bayer and colleagues at the Italian Institute ... growing. In 2012, its production reached 288 million tons ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2
... , Cincinnati, (OH) - The International Rett Syndrome Foundation (IRSF) ... 18 new grants designed to study a variety of diverse ... and outcome measures for Rett syndrome. IRSF is the ... Rett syndrome research with the cumulative total of research spending ...
... German-based project is setting out to rescue biodiversity data at ... institutional databases, are kept in outdated digital storage systems, or ... Botanic Garden and Botanical Museum Berlin-Dahlem, provides a good example ... data. This is one of a set of data ...
... that is associated with the spread of cancer has won ... one of this year,s Kaye Innovation Awards at the university. ... of Prof. Chaim Gilon and Prof. Alexander Levitzki at the ... B (PKB, also called Akt). Since the activation of PKB ...
Cached Biology News:IRSF awards over $1.5 million for basic and translational research for Rett syndrome 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 3German research team targets 'at risk' data on biodiversity 2German research team targets 'at risk' data on biodiversity 3